Sena Tolu1, Aylin Rezvani1, İlhan Karacan2, Derya Bugdayci2, Habib Can Küçük2, Ömer Faruk Bucak2, Teoman Aydin3. 1. Department of Physical Medicine and Rehabilitation, Medipol University Faculty of Medicine, Istanbul, Turkey. 2. Department of Physical Medicine and Rehabilitation, Istanbul Physical Medicine and Rehabilitation Training and Research Hospital, Istanbul, Turkey. 3. Department of Physical Medicine and Rehabilitation, Bezmialem Vakıf University Faculty of Medicine, Istanbul, Turkey.
Abstract
OBJECTIVES: This study aims to investigate medication adherence in Turkish patients with ankylosing spondylitis (AS) and analyze the related factors for non-adherence. PATIENTS AND METHODS: Ninety-nine patients with AS (60 males, 39 females; mean age 41.3±8.4 years; range, 18 to 66 years) were included in the study. Sociodemographic and clinical data were collected. Disease activity (Bath Ankylosing Spondylitis Disease Activity Index, C-reactive protein, and erythrocyte sedimentation rate), functional status (Bath Ankylosing Spondylitis Functional Index), spinal pain and fatigue (visual analog scale), quality of life (Ankylosing Spondylitis Quality of Life), and depression and anxiety (Hospital Anxiety and Depression Scale) were evaluated. Adherence to anti-rheumatic drugs was elicited using the Compliance Questionnaire on Rheumatology (CQR). Medication beliefs were assessed using the Beliefs about Medicines Questionnaire (BMQ), and illness perception using the Brief Illness Perception Questionnaire (B-IPQ). RESULTS: Non-adherence was reported in 64 patients (64.6%). No significant relationship between demographic, clinical, or psychological factors and adherence was found, except for disease duration (p=0.031). High B-IPQ treatment follow-up, illness coherence, and BMQ-Specific necessity scores were associated with good adherence (p=0.007, p=0.039, and p=0.002, respectively). BMQ-General overuse and harm scores showed an inverse correlation with the CQR score (p=0.005 r=-0.278; p=0.029 r=-0.219, respectively). Longer disease duration [odds ratio (OR): 0.98, 95% confidence interval (CI): 0.97-0.99] and higher B-IPQ item-1 score regarding the effect of the illness on the individual's life (OR: 0.58, 95% CI: 0.42- 0.81) were important predictors of low adherence. CONCLUSION: Nearly three out of five AS patients were identified as at risk for non-adherence with the CQR. Medication adherence is influenced by the patient's beliefs about medicines and illness perceptions, and these may be key targets for future interventions to improve medication adherence.
OBJECTIVES: This study aims to investigate medication adherence in Turkish patients with ankylosing spondylitis (AS) and analyze the related factors for non-adherence. PATIENTS AND METHODS: Ninety-nine patients with AS (60 males, 39 females; mean age 41.3±8.4 years; range, 18 to 66 years) were included in the study. Sociodemographic and clinical data were collected. Disease activity (Bath Ankylosing Spondylitis Disease Activity Index, C-reactive protein, and erythrocyte sedimentation rate), functional status (Bath Ankylosing Spondylitis Functional Index), spinal pain and fatigue (visual analog scale), quality of life (Ankylosing Spondylitis Quality of Life), and depression and anxiety (Hospital Anxiety and Depression Scale) were evaluated. Adherence to anti-rheumatic drugs was elicited using the Compliance Questionnaire on Rheumatology (CQR). Medication beliefs were assessed using the Beliefs about Medicines Questionnaire (BMQ), and illness perception using the Brief Illness Perception Questionnaire (B-IPQ). RESULTS: Non-adherence was reported in 64 patients (64.6%). No significant relationship between demographic, clinical, or psychological factors and adherence was found, except for disease duration (p=0.031). High B-IPQ treatment follow-up, illness coherence, and BMQ-Specific necessity scores were associated with good adherence (p=0.007, p=0.039, and p=0.002, respectively). BMQ-General overuse and harm scores showed an inverse correlation with the CQR score (p=0.005 r=-0.278; p=0.029 r=-0.219, respectively). Longer disease duration [odds ratio (OR): 0.98, 95% confidence interval (CI): 0.97-0.99] and higher B-IPQ item-1 score regarding the effect of the illness on the individual's life (OR: 0.58, 95% CI: 0.42- 0.81) were important predictors of low adherence. CONCLUSION: Nearly three out of five AS patients were identified as at risk for non-adherence with the CQR. Medication adherence is influenced by the patient's beliefs about medicines and illness perceptions, and these may be key targets for future interventions to improve medication adherence.
Authors: Nicola Dalbeth; Keith J Petrie; Meaghan House; Jimmy Chong; Wingchi Leung; Rini Chegudi; Anne Horne; Greg Gamble; Fiona M McQueen; William J Taylor Journal: Arthritis Care Res (Hoboken) Date: 2011-11 Impact factor: 4.794
Authors: M T Duruöz; L Doward; Y Turan; L Cerrahoglu; M Yurtkuran; M Calis; N Tas; S Ozgocmen; O Yoleri; B Durmaz; S Oncel; T Tuncer; O Sendur; M Birtane; F Tuzun; U Bingol; M Kirnap; G Celik Erturk; O Ardicoglu; A Memis; F Atamaz; R Kizil; C Kacar; G Gurer; K Uzunca; H Sari Journal: Rheumatol Int Date: 2013-06-14 Impact factor: 2.631
Authors: Catharine Morgan; John McBeth; Lis Cordingley; Kath Watson; Kimme L Hyrich; Deborah P M Symmons; Ian N Bruce Journal: Rheumatology (Oxford) Date: 2015-05-13 Impact factor: 7.580
Authors: Young Sun Suh; Yun-Hong Cheon; Hyun-Ok Kim; Rock-Bum Kim; Ki Soo Park; Sang-Hyon Kim; Seung-Geun Lee; Eun-Kyoung Park; Jian Hur; Sang-Il Lee Journal: Korean J Intern Med Date: 2017-04-20 Impact factor: 2.884
Authors: Ruifu Sun; Xuesong Wang; Xiaohong Sun; Bing Zhao; Xiugong Zhang; Xiaojin Gong; Sunny Hei Wong; Matthew Tak Vai Chan; William Ka Kei Wu Journal: Front Immunol Date: 2022-02-10 Impact factor: 7.561